 --CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. NASDAQ:CLDX today reported interim data from the Companys ongoing, open label clinical trial of CDX-0159 in patients with antihistamine refractory cold contact urticaria ColdU and symptomatic dermographism SD, the two most common forms of chronic inducible urticaria CIndU. In all patients treated and assessed for at least 15 days after treatment n10, 8 of 10 patients 80 experienced a complete response CR to provocation testing post-treatment and one patient experienced a partial response PR. CDX-0159 was generally well tolerated. CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. Enrollment is currently being completed in the ColdU and SD cohorts 10 per cohort; 20 total. Based on these compelling results, the study will be expanded to also include 10 patients with cholinergic urticaria. The Company will host a conference call at 7:45 am ET today to discuss results and will be joined by Dr. Marcus Maurer, Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin, who is conducting the study. 